Artemisinin Suppressed Melanoma Recurrence and Metastasis After Radical Surgery Through the KIT/PI3K/AKT Pathway

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2025 Jan 2

PMID 39744440

Authors

Zhiwei Zhou

Mohd Farhan

Xingan Xing

Wenshu Zhou

Ruohong Lin

Shan Zeng

Mengfang Li

Wenhua Zheng

Affiliations

Soon will be listed here.

Abstract

Cancer radical surgery is the primary treatment for melanoma, but almost all malignant melanoma patients get recurrence and metastasis after surgery and are eventually dead. This clinical dilemma appeals to better drugs for post-surgery therapy. Artemisinin is a safe and effective antimalarial drug used in the clinic for decades. However, no information is available regarding the effect of Artemisinins on melanoma recurrence and metastasis after tumor excision. In the present study, we established a post-surgery tumor model on balb/c nude mice, and we found that subclinical dosages of Artemisinin significantly blocked recurrence, metastasis, and extended survival time of mice after tumor excision. Similar results were obtained in the experiments with B16 and A375 cell lines. Further experiments confirmed that Artemisinin inhibits melanoma and after radical surgery by the c-KIT/PI3K/AKT signaling pathway. Our findings support the therapeutic potential of Artemisinin in malignant melanoma after surgery.

References

Efferth T . From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol. 2017; 46:65-83. DOI: 10.1016/j.semcancer.2017.02.009. View

Bhave P, Haydon A . Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises. Australas J Dermatol. 2020; 61(3):203-209. DOI: 10.1111/ajd.13309. View

Lowe L . Metastatic melanoma and rare melanoma variants: a review. Pathology. 2023; 55(2):236-244. DOI: 10.1016/j.pathol.2022.11.006. View

Carvajal R, Lawrence D, Weber J, Gajewski T, Gonzalez R, Lutzky J . Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015; 21(10):2289-96. PMC: 5013827. DOI: 10.1158/1078-0432.CCR-14-1630. View

Thanaketpaisarn O, Waiwut P, Sakurai H, Saiki I . Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways. Int J Oncol. 2011; 39(1):279-85. DOI: 10.3892/ijo.2011.1017. View

Deeken J, Wang H, Hartley M, Cheema A, Smaglo B, Hwang J . A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2018; 81(3):587-596. DOI: 10.1007/s00280-018-3533-8. View

Martelli A, Nyakern M, Tabellini G, Bortul R, Tazzari P, Evangelisti C . Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia. 2006; 20(6):911-28. DOI: 10.1038/sj.leu.2404245. View

Cabello C, Lamore S, Bair 3rd W, Qiao S, Azimian S, Lesson J . The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. Invest New Drugs. 2011; 30(4):1289-301. PMC: 3203350. DOI: 10.1007/s10637-011-9676-7. View

Guo J, Si L, Kong Y, Flaherty K, Xu X, Zhu Y . Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011; 29(21):2904-9. DOI: 10.1200/JCO.2010.33.9275. View

10.

Davies M, Gershenwald J . Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am. 2010; 20(1):165-80. PMC: 3031081. DOI: 10.1016/j.soc.2010.09.003. View

11.

Yu H, Hou Z, Tian Y, Mou Y, Guo C . Design, synthesis, cytotoxicity and mechanism of novel dihydroartemisinin-coumarin hybrids as potential anti-cancer agents. Eur J Med Chem. 2018; 151:434-449. DOI: 10.1016/j.ejmech.2018.04.005. View

12.

Kang X, Shi X, Chen W, Pu X, Sun Z, Halifu Y . Analysis of KIT mutations and c-KIT expression in Chinese Uyghur and Han patients with melanoma. Clin Exp Dermatol. 2015; 41(1):81-7. DOI: 10.1111/ced.12659. View

13.

Shi X, Wang L, Ren L, Li J, Li S, Cui Q . Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells. Phytother Res. 2019; 33(5):1413-1425. DOI: 10.1002/ptr.6332. View

14.

Huang N, Lee K, Stark M . Current Trends in Circulating Biomarkers for Melanoma Detection. Front Med (Lausanne). 2022; 9:873728. PMC: 9038522. DOI: 10.3389/fmed.2022.873728. View

15.

Meng D, Carvajal R . KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. Am J Clin Dermatol. 2019; 20(3):315-323. DOI: 10.1007/s40257-018-0414-1. View

16.

Turri-Zanoni M, Medicina D, Lombardi D, Ungari M, Balzarini P, Rossini C . Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases. Head Neck. 2012; 35(8):1066-77. DOI: 10.1002/hed.23079. View

17.

Efferth T . Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin--from bench to bedside. Planta Med. 2007; 73(4):299-309. DOI: 10.1055/s-2007-967138. View

18.

Schadendorf D, Fisher D, Garbe C, Gershenwald J, Grob J, Halpern A . Melanoma. Nat Rev Dis Primers. 2016; 1:15003. DOI: 10.1038/nrdp.2015.3. View

19.

Jenkins R, Fisher D . Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2020; 141(1):23-31. PMC: 7541692. DOI: 10.1016/j.jid.2020.03.943. View

20.

Dwivedi A, Mazumder A, du Plessis L, du Preez J, Haynes R, Du Plessis J . In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells. Nanomedicine. 2015; 11(8):2041-50. DOI: 10.1016/j.nano.2015.07.010. View